Literature DB >> 16786739

[Correlations between serum matrix metalloproteinase (MMP-1, MMP-3, MMP-9, MMP-13) concentrations and markers of disease activity in early rheumatoid arthritis].

Małgorzata Fiedorczyk1, Piotr Adrian Klimiuk, Stanisław Sierakowski, Izabela Domysławska, Justyna Chwiećko.   

Abstract

The purpose of this study was to analyse the correlations between serum concentrations of the matrix metalloproteinases (MMP-1, MMP-3, MMP-9, MMP-13) and clinical markers of disease activity in patients with early rheumatoid arthritis (RA). The study group consisted of 30 RA patients, untreated with disease modifying antirheumatic drugs (DMARDs) or corticosteroids, with disease duration less than 3 years. The analysis of serum concentrations of MMPs was based on a quantitative sandwich ELISA. We observed the positive significant correlations between studied MMPs and clinical markers of disease activity, such as number of swollen joints or erythrocyte sedimentation rate (ESR). Furthermore, we revealed significant correlations between serum MMP-1, MMP-3, MMP-9, MMP-13 concentrations and disease activity score (DAS) (p < 0.01; p < 0.001; p < 0.001; p < 0.05 respectively). We conclude that studied matrix metallo-proteinases might be useful clinical markers of disease activity in early rheumatoid arthritis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16786739

Source DB:  PubMed          Journal:  Przegl Lek        ISSN: 0033-2240


  2 in total

1.  Expression of MMP-3 and TIMP-3 in gastric cancer tissue and its clinical significance.

Authors:  Hong-Qi Liu; Shu Song; Jian-Hua Wang; Shao-Lan Zhang
Journal:  Oncol Lett       Date:  2011-08-31       Impact factor: 2.967

2.  Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-alpha, Oncostatin M and response to biologic therapies.

Authors:  Ellen M Moran; Ronan Mullan; Jennifer McCormick; Mary Connolly; Owen Sullivan; Oliver Fitzgerald; Barry Bresnihan; Douglas J Veale; Ursula Fearon
Journal:  Arthritis Res Ther       Date:  2009-07-23       Impact factor: 5.156

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.